The ARAMIS Trial showed that darolutamide increased overall survival for men with prostate cancer, it delayed the time to the use of cytotoxic chemotherapy as well as improving the important quality of life (QoL) measures of time to pain progression, and time to developing a symptomatic skeletal-related event.
Why is Evaluating Quality of Life (QoL) in Clinical Trials is Important
Palliative care improves a person’d quality of life and it also can extend a person’s survival.
Apalutamide (Erleada) extends time to the development of first metastatic development and it does not degrade the quality of life.
Recently presented data has shown that there is a clinical improvement in median radiologic progression-free survival (rPFS) when olaparib (Lynparza) is used in combination with abiraterone (ZYTIGA) compared to abiraterone alone in men with metastatic castration-resistant prostate cancer (mCRPC).